Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NEXIMMUNE, INC.

(NEXI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

NexImmune, Inc.(NasdaqGM:NEXI) dropped from S&P Global BMI Index

09/20/2021 | 12:00am EDT

NexImmune, Inc.(NasdaqGM:NEXI) dropped from S&P Global BMI Index


© S&P Capital IQ 2021
All news about NEXIMMUNE, INC.
09/27NEXIMMUNE : to Present at the 2021 Cantor Virtual Global Healthcare Conference
AQ
09/20NEXIMMUNE, INC.(NASDAQGM : NEXI) dropped from S&P Global BMI Index
CI
09/10NexImmune to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
GL
08/1115,079,875 Common Stock of NexImmune, Inc. are subject to a Lock-Up Agreement Ending on..
CI
08/11Certain Options of NexImmune, Inc. are subject to a Lock-Up Agreement Ending on 11-AUG-..
CI
08/09NEXIMMUNE : Management's Discussion and Analysis of Financial Condition and Results of Ope..
AQ
08/09Neximmune, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
08/09NEXIMMUNE, INC. : Results of Operations and Financial Condition, Regulation FD Disclosure,..
AQ
08/09NEXIMMUNE : Reports Second Quarter 2021 Financial Results and Provides Business Updates
AQ
08/09NexImmune to Explore the Use of AIM™ Direct Injection Technology in Type 1 Diabet..
GL
More news
Analyst Recommendations on NEXIMMUNE, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -55,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,86x
Yield 2021 -
Capitalization 291 M 291 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 44
Free-Float 72,6%
Chart NEXIMMUNE, INC.
Duration : Period :
NexImmune, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEXIMMUNE, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 12,88 $
Average target price 33,33 $
Spread / Average Target 159%
EPS Revisions
Managers and Directors
Scott Carmer President, Chief Executive Officer & Director
John Trainer Chief Financial Officer
Sol J. Barer Chairman
Jerome B. Zeldis Executive Vice President-Research & Development
Robert Knight Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NEXIMMUNE, INC.0.00%291
GILEAD SCIENCES, INC.14.98%83 993
BIONTECH SE251.28%69 162
WUXI APPTEC CO., LTD.25.77%65 142
REGENERON PHARMACEUTICALS17.86%59 196
VERTEX PHARMACEUTICALS-20.84%48 536